Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Haohuai He

dblp:321/3069 · DBLP profile ↗
← Back
5ranked-venue papers
3as first author
5since 2021 · last 2024
0000-0003-3831-3996ORCID · corroborated

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 3 · 3 first-author · 3 since 2021Artificial intelligence and machine learning · 2 · 2 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
2 papers
Bioinformatics and computational biology · 100%

Topics — the 4 heaviest of 4, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › drug discovery › drug-target interaction prediction
drug-target binding affinity prediction
1.422024
Integrating sequence and graph information for enhanced drug-target affinity prediction · Sci. China Inf. Sci. 2024
NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction · Bioinform. 2023
Bioinformatics and computational biology › drug discovery
drug-target interaction prediction
0.812024
Integrating sequence and graph information for enhanced drug-target affinity prediction · Sci. China Inf. Sci. 2024
Bioinformatics and computational biology
drug discovery
0.712023
NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction · Bioinform. 2023
Bioinformatics and computational biology › drug discovery
drug repurposing
0.212023
NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction · Bioinform. 2023

Methods — techniques the papers use, named apart from their topics

graph neural network · 1.4sequence representation learning · 0.8sequence-based learning · 0.7multi-head self-attention · 0.7
YearPublicationVenuePosition
2024 Integrating sequence and graph information for enhanced drug-target affinity prediction
Haohuai He, Guanxing Chen, Calvin Yu-Chian Chen
Sci. China Inf. Sci.1
2024 GINCM-DTA: A graph isomorphic network with protein contact map representation for potential use against COVID-19 and Omicron subvariants BQ.1, BQ.1.1, XBB.1.5, XBB.1.16
Guanxing Chen, Haohuai He, Qiujie Lv, Calvin Yu-Chian Chen
Expert Syst. Appl.2
2023 NHGNN-DTA: a node-adaptive hybrid graph neural network for interpretable drug-target binding affinity prediction
abstract
MOTIVATION: Large-scale prediction of drug-target affinity (DTA) plays an important role in drug discovery. In recent years, machine learning algorithms have made great progress in DTA prediction by utilizing sequence or structural information of both drugs and proteins. However, sequence-based algorithms ignore the structural information of molecules and proteins, while graph-based algorithms are insufficient in feature extraction and information interaction. RESULTS: In this article, we propose NHGNN-DTA, a node-adaptive hybrid neural network for interpretable DTA prediction. It can adaptively acquire feature representations of drugs and proteins and allow information to interact at the graph level, effectively combining the advantages of both sequence-based and graph-based approaches. Experimental results have shown that NHGNN-DTA achieved new state-of-the-art performance. It achieved the mean squared error (MSE) of 0.196 on the Davis dataset (below 0.2 for the first time) and 0.124 on the KIBA dataset (3% improvement). Meanwhile, in the case of cold start scenario, NHGNN-DTA proved to be more robust and more effective with unseen inputs than baseline methods. Furthermore, the multi-head self-attention mechanism endows the model with interpretability, providing new exploratory insights for drug discovery. The case study on Omicron variants of SARS-CoV-2 illustrates the efficient utilization of drug repurposing in COVID-19. AVAILABILITY AND IMPLEMENTATION: The source code and data are available at https://github.com/hehh77/NHGNN-DTA.
Haohuai He, Guanxing Chen, Calvin Yu-Chian Chen
Bioinform.1
2023 3D graph neural network with few-shot learning for predicting drug-drug interactions in scaffold-based cold start scenario
Qiujie Lv, Ziduo Yang, Haohuai He, Calvin Yu-Chian Chen
Neural Networks4
2022 3DGT-DDI: 3D graph and text based neural network for drug-drug interaction prediction
abstract
MOTIVATION: Drug-drug interactions (DDIs) occur during the combination of drugs. Identifying potential DDI helps us to study the mechanism behind the combination medication or adverse reactions so as to avoid the side effects. Although many artificial intelligence methods predict and mine potential DDI, they ignore the 3D structure information of drug molecules and do not fully consider the contribution of molecular substructure in DDI. RESULTS: We proposed a new deep learning architecture, 3DGT-DDI, a model composed of a 3D graph neural network and pre-trained text attention mechanism. We used 3D molecular graph structure and position information to enhance the prediction ability of the model for DDI, which enabled us to deeply explore the effect of drug substructure on DDI relationship. The results showed that 3DGT-DDI outperforms other state-of-the-art baselines. It achieved an 84.48% macro F1 score in the DDIExtraction 2013 shared task dataset. Also, our 3D graph model proves its performance and explainability through weight visualization on the DrugBank dataset. 3DGT-DDI can help us better understand and identify potential DDI, thereby helping to avoid the side effects of drug mixing. AVAILABILITY: The source code and data are available at https://github.com/hehh77/3DGT-DDI.
Haohuai He, Guanxing Chen, Calvin Yu-Chian Chen
Briefings Bioinform.1